A genome-wide methylation study reveals X chromosome and childhood trauma methylation alterations associated with borderline personality disorder

María J. Arranz, Cristina Gallego-Fabrega, Ana Martín-Blanco, Joaquim Sole, Matilde Elices, Elisabet Domínguez-Clavé, Juliana Salazar, Daniel Vega, Laia Briones-Buixassa and Juan Carlos Pascual

Abstract
Borderline personality disorder (BPD) is a severe and highly prevalent psychiatric disorder, more common in females than in males and with notable differences in presentation between genders. Recent studies have shown that epigenetic modifications such as DNA methylation may modulate gene × environment interactions and impact on neurodevelopment. We conducted an epigenome wide study (Illumina Infinium HumanMethylation450k beadchip) in a group of BPD patients with (N = 49) and without (N = 47) childhood traumas and in a control group (N = 44). Results were confirmed in a replication cohort (N = 293 BPD patients and N = 114 controls) using EpiTYPER assays. Differentially methylated CpG sites were observed in several genes and intragenic regions in the X chromosome (PQBP1, ZNF41, RPL10, cg07810091 and cg24395855) and in chromosome 6 (TAP2). BPD patients showed significantly lower methylation levels in these CpG sites than healthy controls. These differences seemed to be increased by the existence of childhood trauma. Comparisons between BPD patients with childhood trauma and patients and controls without revealed significant differences in four genes (POU5F1, GGT6, TNFRSF13C and FAM113B), none of them in the X chromosome. Gene set enrichment analyses revealed that epigenetic alterations were more frequently found in genes controlling oestrogen regulation, neurogenesis and cell differentiation. These results suggest that epigenetic alterations in the X chromosome and oestrogen-regulation genes may contribute to the development of BPD and explain the differences in presentation between genders. Furthermore, childhood trauma events may modulate the magnitude of the epigenetic alterations contributing to BPD.

Introduction
Borderline personality disorder (BPD) is a severe psychiatric disorder with a prevalence ranging from 0.5 to 5.9%. BPD is characterized by distorted sense of self, unstable interpersonal relationships, strong emotional reactions, and self-harming behaviours. It is also associated with severe psychosocial deterioration and high use of mental health resources. BPD may result from the interaction between genetic and stressful environmental factors such as early childhood traumatic experiences. BPD is relatively more common in females than in males: about 75% of people with a clinical diagnosis of BPD are females. In addition, the disorder is manifested differentially in men and in women, with notable differences in personality traits. However, the reasons behind these gender differences in prevalence and presentation and the biological factors contributing to this disorder are not yet clear.
Twin and family studies have proven the genetic contribution to BPD, with heritability values of 35–67% for BPD. Several studies have associated genetic variants in serotonin (TPH1 and 5-HTT) and COMT genes with BPD. Variants in FKBP5 and CRHR1 genes involved in the regulation of the hypothalamus–pituitary–adrenal (HPA) axis, which is deregulated in psychiatric disorders, were also found associated with BPD risk. Genome-wide association studies have revealed several risk genes (DPYD, PKP4) shared with other psychiatric conditions such as bipolar disorder, major depression and schizophrenia. Finally, several studies have observed altered methylation patterns in serotonin (TPH1 and 5-HTT) and HTR2A genes with BPD. Several studies have associated genetic variants in monoaminergic or HPA axis genes including SLC6A4, COMT, BDNF, TPH1, FKBP5 and CRHR2 associated with BPD. However, these findings have not been consistently replicated.

Recent studies have shown that epigenetic regulation factors such as DNA methylation may modulate gene x environment interactions and impact on neurodevelopment. Environmental factors such as early life stress and childhood maltreatment alter DNA methylation patterns and potentiates maladaptive behaviours and psychiatric disorders. However, relatively few studies have investigated the contribution of epigenetic factors to BPD. In previous studies, we found alterations in methylation patterns of NR3C1 in BPD patients with and without childhood traumas, in agreement with Perroud and collaborators’ results. Altered methylation patterns of HTR2A, MAOA, MAOB and COMT have also been observed in BPD subjects. Finally, a genome-wide methylation study found that BPD and life adverse events were associated with the methylation status of several genes (IL17RA, KCNQ2 and EFNB1, among others).

In summary, there is strong evidence of the genetic and environmental contribution to the aetiology of BPD and epigenetic regulation may act as a modulator of this interaction. The main aim of this study is to discern the epigenetic events contributing to BPD and to investigate the contribution of childhood trauma to those events.

Materials and methods

Participants

**Discovery sample**

A total of N = 140 subjects including 44 healthy controls and 96 individuals with a BPD diagnosis were recruited for the discovery genome-wide DNA methylation study. Given the higher prevalence of BPD in women and to decrease genetic heterogeneity, all recruited individuals were female of Caucasian origin. **Control sample:** Healthy controls (CTL) with no history of mental illness, drug use or treatment with psychotropic medication were recruited from the local population. Control participants completed self-reported questionnaires designed to discard BPD symptoms or the presence of childhood trauma. **BPD sample:** patients were recruited from the outpatient BPD unit from Hospital de la Santa Creu i Sant Pau. Inclusion criteria: (1) BPD diagnosis according to DSM-IV criteria and assessed through two semi-structured diagnostic interviews, (2) age 18–50 years, (3) no current episode of any Axis I disorder according to DSM-IV criteria, and (4) no severe physical conditions such as organic brain syndrome, neurological disease, or mental deficiency. The following clinical scales were used for the assessment: Structured clinical interview for DSM IV axis II personality disorders (SCID II), Revised Diagnostic Interview for Borderlines (DIB-R), McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD), and Childhood Trauma Questionnaire—Short Form (CTQ-SF). This questionnaire retrospectively assesses childhood abuse and neglect. It evaluates five types of childhood trauma: sexual, physical, and emotional abuse, and physical and emotional neglect. The questionnaire provides an overall rating and a specific score for every subscale (from 5 to 25), as well as cut-off points to classify each trauma according to the severity of the exposure. According to previous studies which have described a positive correlation between the severity and the number of type of maltreatments, and the methylation of several genes, we considered a positive history of trauma if severity was at least moderate in two or more subscales (i.e. cut-off scores of 8 or higher for sexual abuse, 10 or higher for physical abuse, 13 or higher for emotional abuse, 10 or higher for physical neglect, and 15 or higher for emotional neglect). According to the CTQ-SF questionnaire, 49 BPD patients fulfilled the criteria for childhood traumatic experiences (BPD+T), whereas 47 did not fulfil the criteria (BPD-T).

**Replication sample**

The replication cohort included 407 subjects (114 CTL and 293 BPD). Healthy controls had no history of mental illness, drug use, or treatment with psychotropic medication. Patients were recruited from the BPD outpatient units of two hospitals (Hospital de la Santa Creu i Sant Pau and the Consorci Sanitari de l’Anoia, Barcelona). The same inclusion criteria were used for the discovery and replication samples. This sample included N = 147 patients with available information for childhood traumatic experiences according to the CTQ-SF. A total of N = 81 patients (BPD+T) fulfilled the criteria of traumatic experiences in childhood, whereas N = 66 patients (BPD-T) did not fulfil the criteria. All patients and controls were assessed by clinical staff experienced in the evaluation of BPD. All participants were also females of Caucasian origin. Almost 90% of BPD+T patients were exposed to moderate to severe emotional abuse and 60%
were exposed to sexual abuse. No significant differences in demographics or clinical severity were observed between BPD patients with and without trauma (Supplementary Table 1).

The study was carried out in accordance with the Declaration of Helsinki and was approved by our research ethics committee. Written informed consent was obtained from all participants who did not receive any economic compensation.

**Methylation studies**

**Genome-wide DNA methylation assay, quality control and pre-processing**

DNA was extracted from whole blood (Autopure Qiagen) following the manufacturer’s instructions. DNA bisulphite treatment and PCR amplification were performed by means of EpiTech Bisulfit and the PyroMark PCR kits (Qiagen), respectively. Samples were randomly distributed for all phenotypes of interest (www.randomizer.org). Genome-wide DNAm was assessed using the Infinium HumanMethylation450K BeadChip (Illumina Inc, San Diego, CA). Quality control (QC) metrics (hybridization rate, bisulfate conversion, number of beads per array and background correction) were examined to determine the success of the bisulphite conversion and subsequent array hybridization. Probe filtering was performed by removing those with detection p values >0.05, and were not represented by a minimum of three beads on the array, as described elsewhere. Samples with poor bisulphite conversion were also removed.

Single-nucleotide polymorphism-related probes and all multi-hit probes were excluded, as described in the ChAMP Bioconductor package. A set of quantile normalizations was performed using a background adjustment between-array normalization and a dye bias correction, following previous recommendations. Multidimensional scaling, principal components (PC) analyses and singular value decomposition were used to check for unknown population structures, possible batch effects, as well as other technical artefacts. Next, the Reference-Based Method was used to adjust the data by cell-type proportion, using the champ.refbase function. Finally, the Combat function, implemented via the ChAMP Bioconductor package, was performed to correct technical batch effects.

**EpiTYPER assay**

High-Resolution Quantitative Methylation Profiling with EpiTYPER® and the MassARRAY® System (Agena Bioscience, San Diego, California), was used to validate the results from the discovery phase. EpiDesigner software for genomic target selection and PCR primer design was used to select top CpG sites from the discovery study suitable to be analysed by EpiTYPER®. Two measures were captured for each CpG site and then averaged to avoid off-measurements. Pairs with a standard deviation bigger than 10% were excluded as part of the quality control.

**Statistical analyses**

**Genome-wide DNA methylation study**

Methylation levels of each CpG site were expressed as β-values, ranging from 0 to 1 (unmethylated and completely methylated, respectively). Differentially methylated CpG sites (DMCs) were calculated using linear models as described in the limma package. Three different analyses were performed. First, DNAm levels were compared between BPD patients and controls (BPD vs. CTL). Second, BPD+T patients were compared to BPD-T patients and controls pooled together (BPD+T vs. CTL & BPD-T). Third, DNAm levels from BPD patients who had experienced childhood trauma were compared with levels from patients without childhood trauma (BPD+T vs. BPD-T). Analyses were adjusted by age, PC, and presence or absence of trauma in the first analysis, and age and PC for the second and third analyses. The two first PCs that accounted for 91% of variability were included in the analyses. Statistical significant values were set at p value <10−07 as described by Rakyan et al. Differentially methylated regions (DMRs) were also calculated using the Bumphunter method; statistical significant values were set at p value <0.05.

**Replication study**

Methylation levels of CpG sites an CpG units were expressed as discreet proportions ranging from 0 to 1 by intervals of 0.2 (0 = unmethylated and 1 = completely methylated). DMCs were tested using general linear models. As in the genome-wide DNA methylation study, three different analyses were performed: BPD vs. CTL, BPD+T vs. BPD-T & CTL, BPD+T vs. BPD-T, using the same models. The R statistical computing environment (3.6.3 version) was used to perform all statistical analyses and plots.

**Gene set enrichment analyses (GSEA)**

The Molecular Signatures Database (MSigDB) was used to identify enriched gene sets. CpG sites with unadjusted p values <10−03 were selected from each discovery analysis, resulting in 723 unique genes from BPD vs. CTL analysis, 1603 from BPD+T vs. BPD−T & CTL and 196 genes from BPD+T vs. BPD−T. We evaluated the overlap between our three gene sets with two MSigDB collections, Gene Ontology (GO) biological processes ontology and Hallmark gene sets. Similar analyses were performed with genes mapping statistically significant DMRs.
Results

Genome-wide DNA methylation study

After applying quality controls, 140 individuals and 424,616 probes (87.4% of the total probes contained in the HumanMethylation450 BeadChip array) were included in the analyses.

The first analysis comparing DNAm levels between BDPS (N = 96) and CTL (N = 44) showed six CpG sites (PQBP1 cg10030436, q value (FDR adjusted p value) = 3.04 × 10^{-2}; intergenic cg07810091, q value = 3.04 × 10^{-2}; ZNF41 cg22713892, q value = 3.15 × 10^{-2}; RPL10 cg02871887, q value = 3.15 × 10^{-2}; intergenic cg24395855, q value = 3.15 × 10^{-2}, TAP2 cg20156774, q value = 4.86 × 10^{-2}) with differential methylation in our multivariate model (considering age, PC, and presence or absence of childhood trauma as covariates (Table 1). All six CpGs had lower methylation levels in BPD patients than in controls (Fig. 1). In general, the differences in methylation levels with controls were clearer in BPD+T patients than in BPD-T individuals (Supplementary Fig. 1).

The second analysis (N = 49 BPD+T patients vs. N = 91 BPD-T & CTL) revealed five CpGs with lower methylation levels in the BPD+T group (POLISFI cg15948871, q value = 3.86 × 10^{-4}; GPR55 cg24915915, q value = 1.15 × 10^{-2}; GGT6 cg04511534, q value = 1.15 × 10^{-2}; TNFRSF13C cg00253346, q value = 1.15 × 10^{-2}; FAM113B cg05478172, q value = 2.61 × 10^{-2}) after adjusting by age and PC (Table 2 and Supplementary Fig. 2).

Comparisons between BPD+T (N = 49) and BPD-T (n = 47) patients did not show statistically significant results at the 1 × 10^{-7} level. However, 4 of the top 20 CpG findings coincided with top findings in the second analysis (intergenic cg24786705, unadjusted p value = 4.11 × 10^{-6}; POLISFI cg15948871, unadjusted p = 1.04 × 10^{-5}; GGT6 cg04511534, unadjusted p = 2.02 × 10^{-5}; SLC22A7 cg16465769, unadjusted p = 2.75 × 10^{-5} (Table 3 and Supplementary Fig. 3). All four CpG sites showed lower methylation levels in BPD+T compared to BPD-T subjects.

Table 1  Top 20 differentially methylated CpG sites resulting from the comparison between BPD (N = 96) and CTL (N = 44) methylation levels.

| CpG site     | P value | Q value | B     | Chr. | Chr. position | Gene   | Gene region |
|--------------|---------|---------|-------|------|---------------|--------|-------------|
| cg10030436   | 1.16E−07| 3.04E−02| 5.94  | X    | 48755633      | PQBP1  | 5'UTR*      |
| cg07810091   | 1.43E−07| 3.04E−02| 5.73  | X    | 15362655      | IGR    |             |
| cg22713892   | 3.21E−07| 3.15E−02| 4.95  | X    | 153575581     | ZNF41  | 5'UTR       |
| cg02871887   | 3.31E−07| 3.15E−02| 4.92  | X    | 47518016      | RPL10  | TSS200      |
| cg24395855   | 3.71E−07| 3.15E−02| 4.81  | X    | 33278296      | IGR    |             |
| cg20156774   | 6.82E−07| 4.82E−02| 4.21  | 6    | 3982903       | TAP2   | Body        |
| cg06753086   | 1.12E−06| 6.29E−02| 3.73  | 1    | 67430099      | IGR    |             |
| cg11780549   | 1.99E−06| 6.29E−02| 3.68  | 17   | 48755716      | ASPSCR1| Body        |
| cg24047905   | 1.40E−06| 6.62E−02| 3.51  | 17   | 3977385       | IGR    |             |
| cg23390865   | 1.70E−06| 6.70E−02| 3.33  | X    | 30174190      | LOC100133957| TSS1500   |
| cg11435369   | 1.74E−06| 6.70E−02| 3.30  | 7    | 55670466      | ADAP1  | Body        |
| cg17322683   | 2.04E−06| 7.22E−02| 3.15  | 6    | 67032472      | RNF39  | 3'UTR       |
| cg12054566   | 2.54E−06| 8.31E−02| 2.93  | X    | 1510000       | CIGT   | 1stExon     |
| cg04432021   | 3.02E−06| 8.48E−02| 2.77  | 17   | 48534493      | FAM101B| TSS1500     |
| cg25375329   | 3.10E−06| 8.48E−02| 2.74  | X    | 942874        | RNF113A| TSS1500     |
| cg19880947   | 3.19E−06| 8.48E−02| 2.71  | 17   | 145011888     | SLC43A2| Body        |
| cg11147309   | 3.52E−06| 8.49E−02| 2.62  | 8    | 45737011      | PLEC1  | Body        |
| cg11020638   | 3.63E−06| 8.49E−02| 2.59  | 17   | 1818886       | STAT5A | Body        |
| cg07478007   | 3.80E−06| 8.49E−02| 2.55  | 1    | 27188505      | ATAD3B | Body        |
| cg16069147   | 4.19E−06| 8.89E−02| 2.45  | 11   | 65550444      | AOR8K1 | TSS1500     |

Q value indicates FDR corrected p values. B indicates log-odds that the gene is differentially expressed.

Bold letters represent statistically significant results.

*CpGs in two studies: BPD vs. CTL and BPD+T vs. BPD-T & CTL.
Interestingly, five of the six most significant CpGs findings in the BPD vs. CTL comparison (first analysis) were in the X chromosome whereas no statistically significant associations were detected with X chromosome CpG sites in the other two analyses. Supplementary Figure 4 shows all Manhattan and Quantile–Quantile (Q–Q) plots of DMCs resulting from different comparisons.

GSEA of CpG results, using GO biological processes gene sets, revealed a significant presence of genes involved in neurogenesis, neuron and cell differentiation and cell transport when comparing BPD patients and control individuals (Supplementary Table 2). Similar findings were observed when investigating genes with CpG sites differentially methylated between BPD+T patients vs. CTL and BPD-T individuals, with regulation of cell differentiation and neurogenesis being the top findings (Supplementary Table 3). GSEA analyses of the results from BPD+T vs. BPD-T comparisons revealed a significant presence of DMCs in genes involved in cellular macromolecule location and in extracellular structure organization (Supplementary Table 4). GSEA using the Hallmark database showed a significant number of DMCs in genes involved in early and late oestrogen response and myogenesis when comparing BPD vs. CTL and BPD+T vs. CTL & BPD-T (Supplementary Tables 5 and 6). However, no statistically significant results were observed when analysing the results of comparing BPD+T vs. BPD-T data.

Comparisons between BPD and CTL subjects revealed 33 DMRs, most of them in the chromosome 6 (major histocompatibility complex locus) and in the X chromosome. GSEA of the 33 genes included within these regions, using GO biological processes gene sets, revealed a significant presence of genes involved in antigen processing and presentation, and in immune response (Supplementary Table 7). Analysis of BPD+T patients vs. CTL and BPD-T individuals uncovered 16 DMR regions that were enriched for genes involved in embryonic development and regulation of gliogenesis (Supplementary Table 8). Analyses of DMRs in BPD+T vs. BPD-T revealed 13 regions although no significant gene set enrichment within these regions was observed.

Replication study

Four hundred and seven individuals (N = 293 BPDs, including 147 with childhood trauma information −81 BPD+T and 66 BPD−T−, and N = 114 CTL) and 15 CpG sites (top results from analyses 1, 2 and 3 plus 2 CpGs not statistically significant that were amongst the top findings in two comparisons) were included in the replication study. Five of the selected CpGs (ZNF41 cg22713892; TAP2 cg20156774; BNIP3 cg05762616; GGT6
 cg04511534; SLC22A7 cg16465769) were not suitable for EpiTYPER analyses and only ten CpGs were studied (Supplementary Table 9). All samples and amplicons passed Quality Control analyses. Only two of the four CpGs investigated were found statistically significant (PQBP1 cg10030436, \( p = 1.84 \times 10^{-2} \) and RPL10 cg02871887, \( p = 2.24 \times 10^{-2} \)) when comparing BPD and CTL subjects. Nevertheless, the methylation levels in all CpGs investigated were lower in BPD patients than in controls, coinciding with the findings in the discovery study.

The PXDN CpG (cg10888111) was found differentially methylated in the BPD+T vs. BPD−T & CTL comparison (\( p = 5.33 \times 10^{-4} \)), and in the BPD+T vs. BPD−T comparison (\( p = 3.26 \times 10^{-3} \)). BPD+T subjects showed lower methylation levels in both analyses, mirroring the findings of the discovery study. Interestingly, the PXDN cg10888111 was also found differentially methylated when comparing BPD and CTL subjects in the replication study (\( p = 2.25 \times 10^{-4} \)), although it was not found statistically significant in the EWAS. No other significant association was found in the replication study, although the direction of the epigenomic alterations coincided with that of the discovery study.

**Discussion**

The present study investigated methylation patterns in patients with BPDs in comparison with controls and investigated the possible contribution of childhood traumas to the differences observed.

As expected, different methylation patterns were observed in patients when compared to controls, as well as in individuals with childhood trauma and without. The methylation differences observed between BPD patients and controls did not coincide, in general, with the differences observed when analysing childhood trauma. For instance, comparisons between BPD patients and controls revealed several X chromosome regions differentially methylated, an observation that was not replicated when comparing subjects with or without childhood trauma.

| CpG site | \( P \) value | \( Q \) value | \( B \) | Chr. | Chr. position | Gene | Gene region |
|----------|--------------|--------------|--------|------|----------------|------|-------------|
| cg15948871 | 9.09E−10 | 3.86E−04 | 10.57 | 6 | 31139620 | POU5F1 | TSS1500 |
| cg24915915 | 6.01E−08 | 1.15E−02 | 6.45 | 2 | 231799064 | GPR55 | IGR |
| cg04511534 | 8.10E−08 | 1.15E−02 | 6.16 | 17 | 4463371 | GGT6 | Body |
| cg00253346 | 1.09E−07 | 1.15E−02 | 5.87 | 22 | 43234281 | TNFRSF13C | IGR |
| cg05478172 | 3.07E−07 | 1.15E−02 | 4.86 | 12 | 47628981 | PQBP1 | 5'UTR |
| cg16465769 | 7.10E−07 | 5.03E−02 | 4.04 | 6 | 31139620 | GGT6 | Body |
| cg00253346 | 8.10E−08 | 1.15E−02 | 5.87 | 17 | 4463371 | GGT6 | Body |

\( Q \) value indicates FDR corrected \( p \) values. \( B \) indicates log-odds that the gene is differentially expressed. Bold letters represent statistically significant results.

\*Cpgs in two studies: BPD+T vs. BPD−T & CTL and BPD+T vs. BPD−T.

\*\*Cpgs in two studies: BPD vs. CTL and BPD+T vs. BPD−T & CTL.
These X chromosome epigenomic alterations may partially explain the different gender prevalence and presentation of BPD. In support of this hypothesis, gene enrichment analyses also revealed epigenomic alterations in genes controlling oestrogen regulation, although further confirmation of these findings is required. Methylation alterations were also observed in genes involved in neurogenesis, neuron differentiation, development, regulation and morphogenesis, as revealed by the GSEA, whereas DMRs analyses revealed enrichment of genes involved in the regulation of immune response processes.

The discovery study revealed that methylation levels of 5 X chromosome CpG sites within the \(\textit{PQBP1}, \textit{ZNF41}, \textit{RPL10}\) genes and two intragenic regions were lower in BPD patients than in controls. Additionally, a CpG site in the transporter 2 member of the ATP-binding cassette subfamily B (\(\textit{TAP2}\), chromosome 6) was also found to be less methylated in BPD patients than in controls. The Polyglutamine binding protein 1 (\(\textit{PQBP1}\)) is involved in transcription activation. \(\textit{PQBP1}\) mutations have been linked with intellectual disability and neurodegenerative disorders\(^2\) and with Renpenning syndrome\(^3\). The zinc-finger protein 41 (\(\textit{ZNF41}\)) participates in nucleic acid binding and transcription regulation. \(\textit{ZNF41}\) mutations have been associated with cognitive deficits\(^4\). However, this finding was not confirmed in later studies\(^5\). The ribosomal protein L10 (\(\textit{RPL10}\)) is a component of the 60S ribosomal subunit and participates in RNA binding and transcription and translation regulation. \(\textit{RPL10}\) dysfunction disrupts neurodevelopment and causes X-linked ribosomopathy characterized by syndromic intellectual disability and epilepsy\(^6\). \(\textit{RPL10}\) mutations have been linked to autism spectrum disorder (\(\textit{ASD}\)) mechanisms\(^7\). Cognitive and personality traits share common genetic factors and symptomatology\(^8\). For instance, impulsivity and emotional dysregulation are symptoms common to individuals with personality disorders or significant intellectual disability\(^9\). These epigenetic alterations may partially explain the similarities in symptomatology between BPD, \(\textit{ASD}\) and intellectual disability. Another X chromosome intragenic CpG island (cg24395855) found to be associated with BPD risk is within a region not

| CpG site          | P value       | Q value       | B   | Chr. | Chr. Position | Gene | Gene region |
|-------------------|---------------|---------------|-----|------|---------------|------|-------------|
| cg01652665        | 1.25E−06      | 5.30E−01      | 3.71| 14   | 36987722      | NCO2-1| Body        |
| cg24786705        | 4.11E−06      | 8.73E−01      | 2.55| 5    | 34500318      | IGR\(^a\) |
| cg10888111        | 6.44E−06      | 9.11E−01      | 2.12| 2    | 16370686      | POU5F1| TSS1500\(^a\) |
| cg15948871        | 1.01E−05      | 9.46E−01      | 1.68| 6    | 31139620      | BNIP3 | Body        |
| cg05762616        | 1.41E−05      | 9.46E−01      | 1.35| 10   | 133787150     | IGR   |
| cg13911052        | 1.47E−05      | 9.46E−01      | 1.32| 2    | 176978909     | IGR   |
| cg24846397        | 1.56E−05      | 9.46E−01      | 1.26| 10   | 133787150     | IGR   |
| cg24915915        | 1.99E−05      | 9.54E−01      | 1.02| 2    | 231799064     | IGR   |
| cg04511534        | 2.02E−05      | 9.54E−01      | 1.01| 17   | 4463371       | IGR   |
| cg16465769        | 2.75E−05      | 0.999985      | 0.71| 6    | 43266151      | IGR   |
| cg01862363        | 3.21E−05      | 0.999985      | 0.56| 17   | 8928028       | IGR   |
| cg12575928        | 3.37E−05      | 0.999985      | 0.51| 11   | 22687660      | IGR   |
| cg02481697        | 3.68E−05      | 0.999985      | 0.43| 17   | 8928012       | IGR   |
| cg20989454        | 3.82E−05      | 0.999985      | 0.39| 11   | 613478        | IGR   |
| cg24319547        | 3.90E−05      | 0.999985      | 0.37| 6    | 33168857      | IGR   |
| cg17207064        | 4.08E−05      | 0.999985      | 0.33| 2    | 17982866      | IGR   |
| cg00914033        | 4.58E−05      | 0.999985      | 0.22| 10   | 81664698      | IGR   |
| cg27190024        | 4.82E−05      | 0.999985      | 0.17| 7    | 94034528      | IGR   |
| cg10969178        | 5.55E−05      | 0.999985      | 0.03| 6    | 31838402      | IGR   |
| cg06759559        | 6.37E−05      | 0.999985      | —0.10| 1    | 7028331       | IGR   |

\(Q\) value indicates FDR corrected \(p\) values. \(B\) indicates log-odds that the gene is differentially expressed.

\(^a\)CpGs in two studies: BPD+T vs. BPD-T & CTL and BPD+T vs. BPD-T.
previously associated with mental disorders or its symptomatology. Less clear is the link observed between BPD risk and low methylation of the TAP2 gene, involved in antigen presentation. Mutations in TAP2 have been associated with several diseases including cancer, tuberculosis, diabetes and arthritis although no link to mental disorders has been reported.

Interestingly, the differences in methylation levels were bigger when comparing BPD patients with trauma vs. controls than when comparing BPD without trauma vs. controls. These observations suggest that childhood trauma confers epigenomic alterations that modulate or increase BPD presentation and symptomatology.

Epigenome wide comparisons between BPD+T and BPD-T & CTLs revealed significant differences in the level of methylation of CpG islands in five genes, including **POU5F1**, **GPR55**, **GGT16**, **TNFRSF13C**, and **FAM113B**, none of them located in the X chromosome. The methylation levels of these islands were lower in BPD patients with childhood trauma than in BPD patients without childhood trauma and controls. The **POU5F1** (OCT4) is a transcription factor that plays a key role in embryonic development and stem cell pluripotency, and it has been linked to several forms of cancer. The **GPR55** gene codes for a putative G-protein-coupled cannabinoid receptor that activates a variety of transduction signal pathways. **GPR55** polymorphisms have been associated with anorexia nervosa, cancer and Crohn’s disease and it has been hypothesized to play a potential role in obesity. No clear links between this receptor and mental disorders has been reported, although in a previous study increased levels of **GPR55** were found in mouse models of RETT syndrome. **GGT16** is a gamma-glutamyltransferase that plays a key role in glutathione homoeostasis by providing substrates for its synthesis. It has been associated with cancer and rheumatoid arthritis with no links with mental disorders. **TNFRSF13C** enhances B cell survival and regulates B cell population. Recently, a microdeletion in 22q including this gene was associated with intellectual disability and obesity. The **FAM113B** gene has also been associated with intellectual disability and obesity. Interestingly, an EWAS study performed that childhood trauma altered the methylation levels of these genes when comparing BPD patients and controls, and none of these differences reached statistical significance. Differences in sample size and sites analysed may explain this discrepancy. Interestingly, an EWAS study performed in BPD patients also found epigenomic alterations in genes involved in cell and neurogenesis regulation associated with the severity of the disorder, with their top finding in the X chromosome. However, their results are not comparable to ours as male and female BPD patients were compared to major depression patients in their study, with no general population controls considered.

Our sample has several limitations. First, the moderate sample size used in the discovery sample hinders the reliability of the results. To minimize false-positive findings, we investigated the top findings in a second larger replication sample. Most of the investigated findings were confirmed in the replication sample, or showed similar directions as in the discovery study, confirming their reliability. Secondly, the controls used in the discovery sample did not experience childhood trauma according to
the questionnaires and childhood trauma data were not available in all replication samples. This information might help to infer the contribution of childhood trauma to epigenomic changes. Thirdly, smoking habits were not considered in the analyses, although they are similar in BPD patients and unaffected individuals. Fourthly, we did not have detailed information on comorbidities (i.e. ADHD or affective disorders) nor on pharmacological treatment received by the study subjects. Both issues may hinder the analyses and difficult the obtention of clear results. Additionally, we did not have data on body mass index, socioeconomic status or education and did not include these variables in the analyses. Fourthly, cell-type proportions were not known in the replication sample, so the results of our discovery study may not be entirely reproducible in the replication study. Finally, although we conducted our study on DNA extracted from blood cells instead of brain tissue, there is a high correlation ($r = 0.86$) between blood and brain methylation status.

In summary, we found epigenomic alterations in X chromosome and oestrogen regulation genes that may contribute to the development of BPD and explain, at least partially, the differences in presentation between genders. Furthermore, childhood trauma events modulated the magnitude of the epigenomic alterations contributing to BPD, confirming previous findings.

Acknowledgements

We would like to thank all the study participants for their kind contribution. This study was supported by Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and a grant from Instituto de Salud Carlos III (PI14/ 00214) and co-financed by the European Regional Development Fund (ERDF).

Author details

1Fundación Docencia e Recerca Mutua Terrassa, Terrassa, Spain. 2Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Barcelona, Spain. 3Stroke Pharmacogenomics and Genetics Group, Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Barcelona, Spain. 4Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 5Department of Psychiatry and Forensic Medicine & Institute of Neuroscience, Universitat Autònoma de Barcelona, Bellaterra, Spain. 6Translational Medical Oncology Laboratory, Institut de Recerca Biomèdica Sant Pau (IIB-Sant Pau), Bellaterra, Spain. 7Psychiatry and Mental Health Department, Hospital of Igualada, Comorci Sanitarie de l’Anoia & Fundació Sanitària d’Igualada, Igualada, Spain

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41398-020-01139-z).

Received: 18 March 2020 Revised: 2 December 2020 Accepted: 7 December 2020 Published online: 05 January 2021

References

1. Widiger, T. A. & Weissman, M. M. Epidemiology of borderline personality disorder. Hosp. Community Psychiatry 42, 1015–1021 (1991).
2. Basir, N. A. et al. Past, present, and future of genetic research in borderline personality disorder. Curr. Opin. Psychol. 21, 60–68 (2018).
3. Alvarez-Tomás, I. et al. Long-term course of borderline personality disorder: a prospective 10-year follow-up study. J. Pers. Disord. 31, 590–605 (2017).
4. Beauchaine, T. P., Klein, D. N., Crowell, S. E., Derbridge, C. & Gatze-Kopp, L. Multifinality in the development of personality disorders: a biology x sex x environment interaction model of antisocial and borderline traits. Dev. Psychopathol. 21, 735–770 (2009).
5. Crowell, S. E., Beauchaine, T. P. & Linehan, M. M. A biosocial developmental model of borderline personality: elaborating and extending Linehan’s theory. Psychol. Bull. 135, 495–510 (2009).
6. Porter, C. et al. Childhood adversity and borderline personality disorder: a meta-analysis. Acta Psychiatr. Scand. 141, 6–20 (2020).
7. Ten Have, M. et al. Prevalence rates of borderline personality disorder symptoms: a study based on the Netherlands Mental Health Survey and Incidence Study-2. BMC Psychiatry 26, 307–316 (2016).
8. Skoglund, C. et al. Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population. Mol. Psychiatry (2019).
9. Sansone, R. A. & Sansone, L. A. Gender patterns in borderline personality disorder. Innov. Clin. Neurosci. 8, 16–20 (2011).
10. Arnaud, A., Ramoz, N., Thomas, P., Jardi, R. & Cowen, P. Genetics of borderline personality disorder: systematic review and proposal of an integrative model. Neurosci. Biobehav. Rev. 40, 6–19 (2014).
11. Martín-Blanco, A. et al. The role of hypothalamus-pituitary-adrenal genes and childhood trauma in borderline personality disorder. Eur. Arch. Psychiatr. Clin. Neurosci. 266, 307–316 (2016).
12. Witt, S. H. et al. Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia. Transl. Psychiatry 7, e1155 (2017).
13. Martín-Blanco, A. et al. An exploratory association study of the influence of noradrenergic genes and childhood trauma in borderline personality disorder. Psychiatry Res. 229, 589–592 (2015).
14. Arnaud, A., Ramoz, N., Peys, H., Thomas, P. & Cowen, P. FKBP5 gene variants and borderline personality disorder. J. Affect. Disord. 248, 26–28 (2019).
15. Thomas, M. et al. Increased BCNF methylation in saliva, but not blood, of patients with borderline personality disorder. Clin. Epigenet. 10, 109 (2018).
16. Bockmühl, Y. et al. Methylation at the CpG island region upregulates Nr3c1 promoter activity after early-life stress. Epigenetics 10, 247–257 (2015).
17. Perroud, N. et al. Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder. Br. J. Psychiatry 200, 30–35 (2014).
18. Thaler, L. et al. Methylation of BCNF in women with bulimic eating syndromes: associations with childhood abuse and borderline personality disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 54, 43–49 (2014).
19. Tyfka, A. R. et al. Childhood maltreatment and methylation of FK506 binding protein 5 gene (FKBP5). Dev. Psychopathol. 27, 1637–1645 (2015).
20. Marinova, Z., Maier, A., Grußblatt, E., Wodacz, T. K. & Waltz, S. A pilot investigation on DNA methylation modifications associated with complex posttraumatic symptoms in elderly traumatized in childhood. BMC Res. Notes 10, 752 (2017).
21. Nestler, E. J., Péra, C. J., Kundakovic, M., Mitchell, A. & Akbarian, S. Epigenetic mechanisms of mental illness. Neuron 15, 447–463 (2016).
22. Wolf, E. J. et al. Traumatic stress and accelerated DNA methylation age: a meta-analysis. Psychoneuroendocrinology 92, 123–134 (2018).
23. Kuehner, N. J., Bruggeman, E. C., Wen, Z. & Yao, B. Epigenetic regulations in neuropsychiatric disorders. Front. Genet. 10, 268 (2019).
24. Summers, J. A., Colich, N. L., Uddin, M., Armstrong, D. & McLaughlin, K. A. Early experiences of threat, but not deprivation, are associated with accelerated biological aging in children and adolescents. Biol. Psychiatry 85, 268–278 (2019).
25. Bustamante, A. C., Armstrong, D. L. & Uddin, M. Epigenetic profiles associated with major depression in the human brain. Psychiatry Res. 260, 439–442 (2018).
26. Martín-Blanco, A. et al. Association between methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity in borderline personality disorder. J. Psychiatr. Res. 57, 34–40 (2014).
